SEC Filing Summary for Day One Biopharmaceuticals, Inc.

This filing details transactions related to the acquisition of Day One Biopharmaceuticals, Inc. by Servier Pharmaceuticals LLC, which was completed on April 23, 2026. Michael Vasconcelles, Head of Research and Dev., reported the disposal of 4,397 shares of Common Stock. Additionally, all outstanding unvested stock options and restricted stock units held by Vasconcelles became fully vested and were subsequently canceled and converted into the right to receive cash. Specifically, options to purchase 346,000 and 171,000 shares of Common Stock, and RSUs representing 226,000 and 106,875 shares of Common Stock, were part of these transactions. The merger agreement stipulated that each outstanding share of the Company's Common Stock was purchased for $21.50 per share in cash.